Literature DB >> 27059732

Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention.

Chia-Cheng Tseng1,2, Chin-Chou Wang1,3, Chang-Chun Hsiao2, Hung-I Lu4, Steve Leu5, Huang-Chih Chang1,2, Kuo-Tung Huang1,2, Wen-Feng Fang1, Yu-Mu Chen1, Shih-Feng Liu1, Cheng-Ta Yang6, Meng-Chih Lin1, Hon-Kan Yip7,8,9,10,11,12.   

Abstract

Microparticles (MPs) are substantially increased in patients with operable stage non-small cell lung cancer (NSCLC) prior to lung resection surgery. This study tested the hypothesis that there is a decrease in MPs after surgical intervention. Between March 2012 and January 2015, 33 patients who had operable stage NSCLC were consecutively and prospectively enrolled into the study. Additionally, 31 healthy subjects who were consecutively enrolled in the study period served as age- and gender-matched controls. Circulating MPs (EDAc-MPs, EDAp-MPs, PDAc-MPs, PDAp-MPs) were measured by flow cytometry once in control subjects and twice (i.e., prior to and three months later after surgical intervention) in NSCLC patients. Compared with control subjects, these four types of circulating MPs were significantly higher in NSCLC patients prior to operation (all P < 0.005), but did not differ among the controls and NSCLC patients at 3 months after surgery (all P > 0.2). Additionally, a receiver operating characteristic curve (ROC) showed that these four types of MPs were significantly valuable predictors for detecting early stage NSCLC (all P < 0.004). Circulating MPs which were remarkably increased in the operable stage of NSCLC prior to surgery were substantially decreased 3 months later after surgery. These findings show that circulating MPs might be an accessory biomarker for monitoring those of NSCLC after receiving lung resection surgery.

Entities:  

Keywords:  Biomarker; Circulating level of microparticles; Early stage of non-small cell lung cancer; Surgical intervention

Mesh:

Substances:

Year:  2016        PMID: 27059732     DOI: 10.1007/s13277-016-5047-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

1.  Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome.

Authors:  Shosaku Nomura; Shigeru Uehata; Sonoko Saito; Kazuoki Osumi; Yasushi Ozeki; Yukio Kimura
Journal:  Thromb Haemost       Date:  2003-03       Impact factor: 5.249

Review 2.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

Review 3.  Maintenance therapy in advanced non-small cell lung cancer: current status and future implications.

Authors:  Thomas E Stinchcombe; Mark A Socinski
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

4.  Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Frank C Detterbeck; Sandra Zelman Lewis; Rebecca Diekemper; Doreen Addrizzo-Harris; W Michael Alberts
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

5.  Targeted/emerging therapies for metastatic non-small cell lung cancer.

Authors:  Leora Horn
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

6.  Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.

Authors:  Nirmal K Veeramachaneni; Richard H Feins; Briana J K Stephenson; Lloyd J Edwards; Felix G Fernandez
Journal:  Ann Thorac Surg       Date:  2012-06-27       Impact factor: 4.330

7.  Increased levels of platelet-derived microparticles in patients with diabetic retinopathy.

Authors:  Nahoko Ogata; Masahito Imaizumi; Shosaku Nomura; Akira Shozu; Miwa Arichi; Masato Matsuoka; Miyo Matsumura
Journal:  Diabetes Res Clin Pract       Date:  2004-12-10       Impact factor: 5.602

Review 8.  Tumor markers in detection of lung cancer.

Authors:  Joachim Schneider
Journal:  Adv Clin Chem       Date:  2006       Impact factor: 5.394

Review 9.  Lung cancer: potential targets for immunotherapy.

Authors:  Eric Tartour; Laurence Zitvogel
Journal:  Lancet Respir Med       Date:  2013-08-23       Impact factor: 30.700

10.  Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Alessandro Brunelli; Anthony W Kim; Kenneth I Berger; Doreen J Addrizzo-Harris
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

View more
  2 in total

1.  Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms.

Authors:  Wenjuan Zhang; Jiaqian Qi; Shixiang Zhao; Wenhong Shen; Lan Dai; Wei Han; Man Huang; Zhaoyue Wang; Changgeng Ruan; Depei Wu; Yue Han
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

2.  Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients.

Authors:  Chin-Chou Wang; Chia-Cheng Tseng; Huang-Chih Chang; Kuo-Tung Huang; Wen-Feng Fang; Yu-Mu Chen; Cheng-Ta Yang; Chang-Chun Hsiao; Meng-Chih Lin; Chi-Kung Ho; Hon-Kan Yip
Journal:  Oncotarget       Date:  2017-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.